Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sarepta Therapeutics Inc is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 840 staff and has a trailing 12-month revenue of around $835.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $109.94 |
|---|---|
| 52-week range | $61.28 - $120.23 |
| 50-day moving average | $105.35 |
| 200-day moving average | $83.94 |
| Wall St. target price | $130.74 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.29 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $109.94 from 2022-10-03
| 1 week (2022-09-27) | 1.49% |
|---|---|
| 1 month (2022-09-02) | 0.51% |
| 3 months (2022-07-01) | 45.21% |
| 6 months (2022-04-04) | 28.40% |
| 1 year (2021-10-04) | 16.14% |
|---|---|
| 2 years (2020-10-02) | -18.44% |
| 3 years (2019-10-04) | 24.58% |
| 5 years (2017-10-04) | 120.85% |
Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $835.2 million |
|---|---|
| Gross profit TTM | $-165,844,000 |
| Return on assets TTM | -9.51% |
| Return on equity TTM | -83.63% |
| Profit margin | -60.66% |
| Book value | $8.30 |
| Market capitalisation | $9.6 billion |
TTM: trailing 12 months
We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.
Sarepta Therapeutics's shares were split on a 1:6 basis on 12 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.
Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $61.28 up to $120.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.193. This would suggest that Sarepta Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.